Pharma Pioneer

OnCusp Initiates Phase 1 CUSP06 Trial for Platinum-Resistant Ovarian Cancer and Solid Tumors

19 May 2024
3 min read

March 6, 2024 - Biopharmaceutical firm OnCusp Therapeutics has initiated a Phase 1 clinical trial for CUSP06, an innovative CDH6-directed antibody-drug conjugate (ADC). The trial's first patient has been dosed, marking a significant step in the company's journey to bring a new treatment option to patients with platinum-resistant ovarian cancer and other advanced solid tumors.

CUSP06 has been meticulously designed to enhance therapeutic potency, maximize the bystander effect, bolster linker stability, and counteract drug resistance, positioning it as a promising candidate for improved safety and efficacy in treating CDH6-expressing tumors. Preclinical studies indicate that CUSP06 could lead the field in clinical performance.

Bing Yuan, PhD, CEO of OnCusp Therapeutics, expressed enthusiasm about the trial's commencement, highlighting the company's evolution into a clinical-stage entity and its commitment to developing groundbreaking therapies. Eric Slosberg, PhD, the company's Chief Development Officer, emphasized CDH6 as a prime target for ADC therapies due to its overexpression in various cancers while sparing non-tumor tissues.

The multicenter Phase 1 study, registered as NCT06234423, aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of CUSP06 in adult patients. The trial is bifurcated into Phase 1a for dose determination and Phase 1b for a deeper examination of safety and efficacy in specific tumor profiles.

Alexander Spira, MD, PhD, a Principal Investigator for the CUSP06 trial and Clinical Director at NEXT Oncology Virginia, underscored the urgency of finding effective treatments for ovarian cancer, which is both prevalent and deadly. The Phase 1 study represents a significant effort to address the treatment gap in platinum-resistant cases.

CUSP06's formulation includes a proprietary high-affinity antibody targeting CDH6, a protease-cleavable linker, and an exatecan payload, a potent topoisomerase-1 inhibitor. The ADC's design minimizes chemoresistance by being a weak substrate for BCRP/P-gp efflux pumps. OnCusp Therapeutics holds the exclusive rights outside China for CUSP06's development and commercialization, following a partnership with Multitude Therapeutics.

OnCusp Therapeutics, co-founded by Drs. Yuan, Slosberg, and Andy Fu, is based in New York City and is focused on converting innovative preclinical research into cancer treatments. The company has secured a $100 million Series A financing round led by Novo Holdings, OrbiMed, and F-Prime Capital, underscoring its potential in the global oncology market.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

First Patient Treated in IPH6501 Phase 1/2 NHL Trial by Innate Pharma
Pharma Pioneer
2 min read
First Patient Treated in IPH6501 Phase 1/2 NHL Trial by Innate Pharma
19 May 2024
Innate Pharma SA has initiated a Phase 1/2 clinical trial to evaluate the safety and tolerability of IPH6501.
Read →
Kura Oncology Begins Trial of KO-2806 and Cabozantinib for Kidney Cancer
Pharma Pioneer
2 min read
Kura Oncology Begins Trial of KO-2806 and Cabozantinib for Kidney Cancer
19 May 2024
Kura Oncology, Inc. has commenced the first patient dosing with KO-2806, a farnesyl transferase inhibitor (FTI), combined with tyrosine kinase inhibitor (TKI) cabozantinib.
Read →
Syncromune® Showcases Early SYNC-T™ SV-102 Trial Data at AACR 2024
Pharma Pioneer
2 min read
Syncromune® Showcases Early SYNC-T™ SV-102 Trial Data at AACR 2024
19 May 2024
Syncromune®, Inc., will showcase groundbreaking data from their Phase 1 clinical trials of SYNC-T, a pioneering in situ platform therapy tailored for solid tumor cancers.
Read →
Sionna Secures $182M for Cystic Fibrosis Treatment Development to Rival Vertex
Pharma Pioneer
2 min read
Sionna Secures $182M for Cystic Fibrosis Treatment Development to Rival Vertex
19 May 2024
Sionna Therapeutics, based in Massachusetts, has successfully concluded a Series C funding round, raising $182 million.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.